Immunic, Inc.
IMUX
$12.32
$0.131.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.40M | 7.61M | 4.26M | 5.98M | 5.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.33M | 33.24M | 23.33M | 25.99M | 27.08M |
| Operating Income | -35.33M | -33.24M | -23.33M | -25.99M | -27.08M |
| Income Before Tax | -34.10M | -32.59M | -19.30M | -25.58M | -26.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.10M | -32.59M | -19.30M | -25.58M | -26.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.10M | -32.59M | -19.30M | -25.58M | -26.82M |
| EBIT | -35.33M | -33.24M | -23.33M | -25.99M | -27.08M |
| EBITDA | -35.29M | -33.20M | -23.29M | -25.95M | -27.04M |
| EPS Basic | -0.80 | -1.08 | -0.99 | -1.32 | -2.03 |
| Normalized Basic EPS | -0.50 | -0.68 | -0.57 | -0.82 | -1.27 |
| EPS Diluted | -0.80 | -1.08 | -0.99 | -1.32 | -2.03 |
| Normalized Diluted EPS | -0.50 | -0.68 | -0.57 | -0.82 | -1.27 |
| Average Basic Shares Outstanding | 42.51M | 30.14M | 19.43M | 19.39M | 13.22M |
| Average Diluted Shares Outstanding | 42.51M | 30.14M | 19.43M | 19.39M | 13.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |